1. Home
  2. DSP vs CCCC Comparison

DSP vs CCCC Comparison

Compare DSP & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viant Technology Inc.

DSP

Viant Technology Inc.

HOLD

Current Price

$8.79

Market Cap

213.3M

Sector

Technology

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$2.30

Market Cap

185.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DSP
CCCC
Founded
1999
2015
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
213.3M
185.1M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
DSP
CCCC
Price
$8.79
$2.30
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
5
Target Price
$18.50
$7.25
AVG Volume (30 Days)
177.5K
891.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
160.87
43.07
EPS
N/A
N/A
Revenue
$289,235,000.00
$35,584,000.00
Revenue This Year
$17.79
N/A
Revenue Next Year
$17.72
N/A
P/E Ratio
$93.83
N/A
Revenue Growth
29.74
71.44
52 Week Low
$8.11
$1.09
52 Week High
$21.83
$3.64

Technical Indicators

Market Signals
Indicator
DSP
CCCC
Relative Strength Index (RSI) 27.78 63.45
Support Level $8.22 $2.13
Resistance Level $9.20 $2.52
Average True Range (ATR) 0.66 0.15
MACD -0.18 0.06
Stochastic Oscillator 1.14 95.33

Price Performance

Historical Comparison
DSP
CCCC

About DSP Viant Technology Inc.

Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Share on Social Networks: